General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsJ&J vaccine... EFFECTIVE against Delta variant.
Just got the news flash from my WSJ app...
I'll look for a link and post it...
But this is great news, so ALL of the US vaccines are effective against Delta variant.
J&J Chief Scientific Officer, Paul Stoffels:
The new findings "reinforce the ability of the Johnson and Johnson Covid-19 vaccine to help protect the health of people globally"
cilla4progress
(24,728 posts)What daughter got.
underpants
(182,791 posts)boston bean
(36,221 posts)So, I was having some concern as well.
Hubby got Pfizer. I got moderna.
Phoenix61
(17,003 posts)The vaccine triggered the production of antibodies that can neutralize the variant in laboratory testing of eight blood samples, the company said.
LisaL
(44,973 posts)If it works in a test tube, in all likelihood it will work in real life too.
Phoenix61
(17,003 posts)LisaL
(44,973 posts)Not sure how one would get one, though, since it hasn't been recommended. I am expecting Moderna will have boosters for us this fall.
WarGamer
(12,440 posts)LisaL
(44,973 posts)against mutants.
WarGamer
(12,440 posts)But for now... I think the vaccinated are in great shape!!
I'm proud of the Moderna magic in my body... made in the USA, the PATRIOT vaccine.
GulfCoast66
(11,949 posts)But the mRNA technical is looking better and better. It seems the way the vaccine uses the virus spikes, which all this virus has makes it incredibly effective.
Now if we could get 90% of Americans to take it Covid would go away. But that not happening.
God forbid Smallpox comes back. We would lose 20% of our population who discount science.
boston bean
(36,221 posts)So, I assume this is standard practice.
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
PRESS RELEASE PR Newswire
Jul. 1, 2021, 07:59 PM
NEW BRUNSWICK, N.J., July 1, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv.
------snip------
"Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. "With each new dataset, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health."
------snip------
Demonstrated strong neutralizing antibody activity against the Delta (B.1.617.2) variant
A preprint submitted by the Company today to bioRxiv contains a new analysis from blood samples obtained from a subset of participants (n=8) in the Phase 3 ENSEMBLE study. These data showed that the Johnson & Johnson single-shot COVID-19 vaccine elicited neutralizing antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa where high efficacy against severe/critical disease was demonstrated.
In the ENSEMBLE trial, Johnson & Johnson's single-dose COVID-19 vaccine was 85 percent effective against severe/critical disease and demonstrated protection against hospitalization and death. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta (P.2) variants during the study period.
------snip------
This testing indicates that the vaccine is likely effective against the delta variant, but real world data needs to be analyzed to be certain.
Baked Potato
(7,733 posts)Pobeka
(4,999 posts)10% is effective, so is 90%.
Nor does it say how many neutralizing antibodies are produced relative to the wild strain, or apha.
I think if it was as good as pfizer or moderna, they'd be touting the numbers, not just a vague qualifier of "effective".
Please correct me if there are some numbers to back up their claims, I did not see any in the article.